HUNTSVILLE, Ala. — A new clinical trial involving an experimental drug given to President Trump last week at Walter Reed Medical Center is just getting underway in Alabama.
Doctors at the University of Alabama at Birmingham’s Division of Infectious Diseases will be conducting the study on an antibody cocktail developed by pharmaceutical company, Regeneron. The study is one of three outpatient COVID-19 clinical trials being conducted by the University, including an antibody cocktail similar to Regeneron’s made by Lilly.
Researchers say their goal is to identify a medication capable of treating people who have tested positive for COVID-19, early on enough in their illness, so that more severe symptoms can be prevented from taking hold.
“If we can stop the virus in its tracks say in the first 3 or 4 days then we can potential block the consequences,” said Dr. Turner Overton of the University of Alabama at Birmingham.
“We’re trying to prevent you from getting to the point that it gets into your lower respiratory track, that it makes it harder for you to breath, more shortness of breath, and more of a need for supplemental oxygen,” added Dr. Sonya Heath of the University of Alabama at Birmingham.
Right now the Doctors say they are looking to enroll potentially 50 or more participants in each study.
If you are interested in joining a study, the University of Alabama at Birmingham has set up an enrollment hotline at 205-934-6777.